Molecular Imaging of Brain Tumors Using Labeled Technetium-99m 1-Thio-D-Glucose.
Status:
Completed
Trial end date:
2021-02-15
Target enrollment:
Participant gender:
Summary
The study should evaluate the biological distribution of 99mTc-1-thio-D-glucose in patients
with primary brain tumors and recurrence of brain tumors.
The primary objective are:
1. To assess the distribution of 99mTc-1-thio-D-glucose in normal tissues and tumors at
different time intervals.
2. To evaluate dosimetry of 99mTc-1-thio-D-glucose.
3. To study the safety and tolerability of the drug 99mTc-1-thio-D-glucose after a single
injection in a diagnostic dosage.
The secondary objective are:
1. To compare the obtained SPECT imaging results of brain tumors with the data of magnetic
resonance imaging (MRI) and/or positron emission tomography (PET) and immunohistochemical
(IHC) studies of postoperative material.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Tomsk National Research Medical Center of the Russian Academy of Sciences